A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether nilotinib is efficacious in the treatment
of metastatic and/or inoperable melanoma harboring a c-Kit mutation.